| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2012-09-10 | MOR103 (antibody targeting granulocyte-macrophage colony-stimulating factor - GM-CSF) | preclinical | Morphosys (Germany) | Autoimmune diseases - Inflammatory diseases | |
| 2012-09-10 | Atu111 | acute lung injury (ALI) |
preclinical | Silence Therapeutics (UK) | Lung diseases |
| 2012-09-05 | Lucentis® (ranibizumab) | wet age-related macular degeneration (wet AMD) |
Novartis (Switzerland) | Ophtalmological diseases | |
| 2012-09-04 | RPL554 | chronic obstructive pulmonary disease (COPD) | 2 | Verona Pharma (UK) | Respiratory diseases |
| 2012-09-03 | olodaterol, an investigational long-acting beta2-agonist (LABA), and tiotropium, a long-acting muscarinic antagonist (LAMA) | chronic obstructive pulmonary disease (COPD) |
2 | Boehringer Ingelheim (Germany) | Respiratory diseases |
| 2012-09-01 | GSK2586881 | acute lung injury (ALI) acute respiratory distress syndrome (ARDS) |
2 | GSK (UK) | Lung diseases |
| 2012-08-30 | QVA149 (indacaterol 110 mcg/glycopyrronium bromide 50 mcg) | chronic obstructive pulmonary disease (COPD) |
3 | Novartis (Switzerland) | Respiratory diseases |
| 2012-08-29 | ELND005 (Scyllo-inositol) | bipolar 1 disorder | 2 | Elan (Ireland) | CNS diseases |
| 2012-08-27 | trastuzumab emtansine (T-DM1) | HER2-positive metastatic breast cancer |
3 | Roche (Switzerland) | Cancer Oncology |
| 2012-08-26 | LCZ696 | heart failure with preserved ejection fraction (HF-PEF) |
2 | Novartis (Switzerland) | Cardiovascular diseases |
| 2012-08-24 | investigational combination LAMA/LABA (GSK573719 and vilanterol) | chronic obstructive pulmonary disease | 3 | GSK (UK) Theravance (USA) | Respiratory diseases |
| 2012-08-23 | drug-device combination Ciprofloxacin Dry Powder for Inhalation | non-cystic fibrosis bronchiectasis (NCFB) |
3 | Bayer Healthcare (Germany) | Respiratory diseases |
| 2012-08-23 | Cell Bandage | knee repair | 1-2 | Azellon (UK) | Regenerative medicine |
| 2012-08-22 | rozrolimupab (SYM001) | immune thrombocytopenia purpura (ITP) |
2 | Symphogen (Denmark) | Hematologic diseases - Autoimmune diseases |
| 2012-08-17 | AZD8931 | advanced oesophago-gastric cancer | 1 | AstraZeneca (UK) Cancer Research UK (UK) Oxford University (UK) | Cancer - Oncology |
| 2012-08-16 | PLX cells (PLacental eXpanded cells) | thromboangiitis obliterans (Buerger\'s disease) | 2 | Pluristem Therapeutics (Israel) | Rare diseases - Inflammatory diseases - Cardiovascular diseases |
| 2012-08-15 | Jetrea® (ocriplasmin) | symptomatic vitreomacular adhesion or vitreomacular traction (VMT) | 3 | Thrombogenics (Belgium) | Ophtalmological diseases |
| 2012-08-13 | V158866 (fatty acid amide hydrolase (FAAH) inhibitor) | pain | 1 | Vernalis (UK) | CNS diseases |
| 2012-08-13 | Vacc-4x and Revlimid® (lenalidomide) | HIV-Aids | Bionor Pharma (Norway | Infectious diseases | |
| 2012-08-08 | ralimetinib (LY2228820) | ovarian cancer | 1-2 | Eli Lilly (USA - IN) | Cancer - Oncology |
